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1  Introduction
Linezolid is an antimicrobial agent that binds to the bacterial 
ribosome and thereby inhibits protein synthesis. Soon after 
its release as a clinical drug, it became clear that bacteria 
could become resistant to linezolid. The resistance mecha-
nisms are mainly causing alteration of the drug target site, 
but probably efflux might also play a role. The resistance is 
still rare in surveillance studies, but outbreaks of resistant 
clones from hospitals have been observed. So far the main 
mechanisms of resistance are occurrence of mutations in 
ribosomal genes or obtaining plasmids with a gene coding 
for a methyltransferase providing resistance. The most 
 obvious way to avoid resistance may be development of 
derivatives of linezolid overcoming the known resistance 
mechanisms.
2  Linezolid and Its Derivatives
Linezolid belongs to the oxazolidinones, a synthetic drug 
class, and is one of few new drugs on the market for antibiot-
ics in many years. The history of the discovery of linezolid 
has already been extensively reviewed [1–4]. Oxazolidinones 
were primarily identified and patented by E. I. du Pont de 
Nemours & Company (DuPont) in 1978 [5]. DUP-105 and 
DUP-721 were developed as first lead compounds of oxa-
zolidinone antibacterials and showed activity against Gram- 
positive bacteria, but the project was terminated due to lethal 
toxicity in animal models [4, 6]. Later, scientists at Upjohn 
Laboratories started a project in order to modify the original 
compound and produce new oxazolidinones, with better 
antibacterial activities and higher safety levels. Among a 
series of oxazolidinones, PNU-100766 (Linezolid) and 
PNU-100592 (Eperezolid) showed oral efficacy, good water 
solubility, and good activity against Gram-positive bacteria. 
Both of them were further evaluated by phase 1 clinical trials 
but only linezolid proceeded to phase 2 clinical trials due to 
its superior bioavailability. Linezolid was approved by FDA 
in 2000 and marketed as Zyvox™ [4, 7]. Linezolid has been 
employed for treating diseases caused by Gram-positive bac-
teria [8, 9], which include streptococci, vancomycin- resistant 
enterococci (VRE), methicillin-resistant Staphylococcus 
aureus (MRSA), some Gram-negative anaerobic species, 
and Mycobacterium tuberculosis [10–12].
Linezolid (Fig. 22.1a) is proven to be a highly effective 
drug and a good alternative for the treatment of difficult 
infections being able to be administered either intravenously 
or orally. However, it does have some liabilities and can cause 
adverse effects such as interaction with serotonergic agents 
that could lead to serotonin syndrome in patients with depres-
sion, and production of reversible thrombocytopenia and 
bone marrow suppression when given for prolonged periods 
of time [13, 14]. The biggest issue raised by the use of line-
zolid in clinical practice, soon after it was available on the 
market, was the appearance of linezolid-resistant strains of S. 
aureus and enterococci [15, 16]. The mechanisms that confer 
this resistance will be described in following sections of this 
chapter. However, development of derivatives of linezolid to 
overcome this issue is currently underway (Fig. 22.1) [17].
The most important linezolid derivative is currently 
tedizolid (Fig. 22.1b) (formerly torezolid), which was under 
clinical development by Cubist pharmaceuticals for the 
treatment of serious Gram-positive infections. Tedizolid 
phosphate (TR-701) is an inactive prodrug that is chemically 
converted by serum phosphatases to the active form tedizolid 
(TR-700) [18]. Tedizolid phosphate was approved by the 
FDA (20/06/2014) with the commercial name Sivextro™. 
Sivextro is indicated for the treatment of acute bacterial 
skin and skin structure infections (ABSSSI). It is active 
against Gram-positive organisms, including staphylococci, 
enterococci, streptococci, and certain anaerobes [19, 20]. 
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Tedizolid demonstrates a greater potency than linezolid, at 
least  fourfold for all bacteria tested [20]. Of particular inter-
est, were the tested linezolid-resistant S. aureus strains, 
which possess mutations in chromosomal genes encoding 
ribosomal rRNA and proteins, or carrying the horizontally 
transferable cfr gene. Methylation of A2503 of 23S rRNA by 
the Cfr methyltransferase confers resistance to linezolid but 
not to tedizolid because of structural differences between the 
two drugs [21]. Initial studies have also shown that tedizolid 
may not have the negative effects on serotonergic agents and 
thrombocytopenia as linezolid show [22, 23].
Other derivatives under investigation are radezolid and 
sutezolid (Fig. 22.1c, d). Radezolid is a unique oxazolidi-
none because it has activity against fastidious Gram-negative 
bacteria like H. influenzae and M. catarrhalis, as well as 
against Gram-positive bacteria, including MRSA, linezolid- 
resistant staphylococci and enterococci [24]. Radezolid has 
completed two phase 2 clinical trials to date: the first in 
community- acquired pneumonia (CAP) and the second trial 
in complicated skin and skin structure infections (cSSSI) [2]. 
To date, phase III trials have not been initiated [25]. It is 
unclear at this point, based upon published literature, whether 
radezolid has any advantages over linezolid. Sutezolid is 
a linezolid derivative with superior bactericidal activity 
against M. tuberculosis as demonstrated by a Phase 2 clinical 
study [26].
Because linezolid resistance has started to arise by vari-
ous mechanisms, in various bacteria, the development of 
new derivatives seems to be the next step in the battle against 
isolates resistant to this class. The derivatives mentioned ear-
lier in this section demonstrate higher potency and lower 
resistance rates compared to linezolid. Due to their proper-
ties, they could potentially compensate at occasions where 
linezolid-resistant isolates arise. They will probably not yet 
replace linezolid in clinical use, as it is still a widely used 
antibiotic with relatively low incidence of resistance.
3  Mechanism of Action of Linezolid
Early studies of the effect of oxazolidinones pointed to 
 inhibition of protein synthesis in growing bacteria [27] and 
suggested an effect on synthesis initiation, which was also 
supported by later studies [28, 29]. Studies of the effect on 
peptidyl transferase using puromycin reactions reported con-
tradicting results that might be due to the relative unnatural 
conditions of these assays. Other studies demonstrated 
frame-shifting and nonsense suppression [30] and effect on 
fMet-tRNA binding and translocation [31].
The fact that linezolid binds to the peptidyl transferase 
center (PTC) of the bacterial ribosome (illustrated in 
Fig. 22.2) was first indicated by mutations in 23S ribosomal 
RNA conferring resistance [32], 23S mutagenesis studies, 
and cross-linking studies [33, 34]. The site was finally con-
firmed and defined in 2008 by crystal structures of linezolid 
bound to the 50S ribosomal subunit from the archaeon 
Haloarcula marismortui [35] and from the bacterium 
Deinococcus radiodurans [36]. The site is in the bottom of 
the cleft of the 50S ribosomal subunit where the 3′-ends of 
aminoacyl-tRNA and peptidyl-tRNA are positioned for pep-
tide transfer (Fig. 22.2b), and is highly conserved in all bac-
teria. The same site in the ribosome binds other antibiotics 
such as chloramphenicol, clindamycin, tiamulin, and strep-
togramin A, several of which are characterized as peptidyl 
transferase inhibitors. It seems like the size and the environ-
ment of the PTC facilitates binding of a range of antibiotics, 
which at binding interfere with the peptide transfer process. 
They can either disturb the positioning of aminoacyl-tRNA 
or peptidyl-tRNA for peptide transfer or directly block some 
movements required during peptide transfer. How the effect 
will show up in various assays to elucidate the specific 
mechanism will also depend on their exact competition with 
the components of the peptide synthesis apparatus. A very 
Fig. 22.1 Chemical structural 
formula for linezolid (a) and 
three derivatives (b)–(d)
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recent study of ribosome function in a linezolid-resistant 
Staphylococcus epidermidis mutant showed a functional and 
structural adaptation of ribosomes. The study reported an 
increased peptidyl transferase activity, as measured by 
 puromycin reactivity, as well as an enhanced growth rate in 
the presence of linezolid [37]. Even though the very exact 
step of inhibition has not been determined for oxazolidi-
nones and maybe will never be completely elucidated, as 
more than one step might be involved, it can be concluded 
that the general effect of linezolid is inhibition of protein 
synthesis by binding to the peptidyl transferase center of the 
bacterial ribosome and affecting some step directly related to 
the peptidyl transferase reaction.
4  Mechanisms of Resistance
Several ways of resistance to linezolid have been published. 
The very well investigated and proven ones are mutations in 
23S rRNA in the peptidyl transferase area of the ribosome, 
and methylation of 23S rRNA nucleotide A2503. The less 
proven but highly indicative ones are mutations in the ribo-
somal protein L3 and efflux. In addition, mutations in ribo-
somal protein L4 have been connected with reduced linezolid 
susceptibility but the extent of this correlation remains to be 
elucidated. Finally, fitness cost in relation to resistance seems 
to be an issue. The following section will review the present 
knowledge of this field.
4.1  Resistance Caused by 23S rRNA 
Mutations
Although early laboratory investigations suggested that 
resistance to linezolid might be slow to emerge [32, 38], as 
almost all bacteria have multiple copies of the 23S rRNA 
gene, linezolid-resistant strains soon appeared [15, 39]. The 
first linezolid-resistant strains were associated with  mutations 
in domain V of the 23S rRNA genes, mainly G2576U trans-
version. Over time various mutations have been identified in 
domain V of 23S rRNA (Fig. 22.3) and they remain the 
 predominant mutations conferring linezolid resistance [55]. 
The G2576U transversion is the most prevalent mutation 
in linezolid-resistant clinical isolates, including S. aureus, 
coagulase negative staphylococci (CoNS), viridans group 
streptococci, Enterococcus faecium, and Enterococcus fae-
calis [56, 57]. The first reported linezolid-resistant entero-
coccal isolates were obtained from patients treated with line-
zolid as part of the Linezolid Compassionate Use Program 
(1999). They had the G2576U mutation in multiple operons 
of the 23S rRNA genes and with MICs correlating to the 
number of mutated operons [58].
The first clinical isolate of linezolid-resistant S. aureus, with 
a G2576U mutation, was reported in 2001 [15]. Later, this iso-
late was found to contain five copies of the 23S rRNA gene, all 
of which were mutated at position 2576 [59] and again a clear 
correlation between the number of mutated rRNA operons and 
the linezolid MIC was established [40, 60, 61]. Most reports of 
the G2576U mutation in clinical isolates is associated with 
some form of increased or prolonged linezolid treatment, and it 
has been shown that the duration of linezolid exposure and 
dose can affect the number of mutated rRNA operons and thus 
linezolid resistance [62]. Mutant gene-dosage effects have also 
been seen in laboratory- derived linezolid-resistant S. aureus 
mutants and in clinical isolates of linezolid-resistant entero-
cocci [40, 41]. A report from 2011 demonstrated that the 
G2576U mutation was retained in a Staphylococcus haemolyti-
cus isolate even after 30 serial passages in antibiotic-free 
medium [42], although some studies have documented rever-
sion of the G2576U mutation in the absence of linezolid pres-
sure [41, 63]. Therefore prolonged linezolid usage should be 
judicious and minimized in clinical settings.
The linezolid-binding site at the PTC comprises con-
served nucleotides (G2061, A2451, C2452, A2503, U2504, 
G2505, U2506, and U2585), which interact directly with 
linezolid, see Fig. 22.3 [35, 36]. Laboratory derived strains 
selected for linezolid resistance show mutations in either 
nucleotides at the proximity of the binding pocket (2061, 
2452, 2503, 2504, and 2505) or at nucleotides further away 
from it (2032, 2062, 2192 2447, 2453, 2499, 2500, 2576, 
2571, 2572, 2608, and 2612) [32, 36, 38, 43–48, 64–67]. The 
degree of linezolid resistance is not a simple function of the 
Fig. 22.2 (a) A model of the two 
ribosomal subunits in bacteria 
(based on PDB: 4YBB). The 
arrow points to the peptidyl 
transferase center in the middle 
of 50S where the amino acids are 
added together and where 
linezolid binds. (b) A cut-view of 
the 50S subunit (based on PDB: 
2 J00, 2 J01, 2 J02, 2 J03), again 
showing the PTC area in the blue 
circle
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nucleotide-linezolid distance and distal nucleotides that 
do not interact with linezolid directly, as G2576U and 
G2447U can confer significantly high resistance [3].
Acquired resistance to linezolid has been observed in 
various clinical isolates of Gram-positive cocci. A methicillin- 
resistant S. aureus (MRSA) bloodstream isolate, derived 
from a patient exposed to a prolonged course of linezolid, 
developed resistance and had a U2500A mutation in the 23S 
rRNA and a loss of a single copy of the gene in the most 
resistant isolates [41]. Various clinical strains of S. aureus, 
S. epidermidis, E. faecium, E. faecalis that are highly 
 resistant to linezolid show a variety of 23S rRNA mutations 
including G2447U [52], A2503G [45], U2504C [45], 
U2504A [51], and G2505A [68], despite of evidence of fit-
ness cost associated with some of these mutations [60]. 
Some additional mutations of the 23S rRNA operons have 
been reported at positions G2603U [69–71] and C2534U 
[51, 52] but direct relationship between these mutations and 
linezolid resistance is not yet established.
Up to date, G2576U is the most common mutation found 
in clinical isolates [72]. In addition, the U2500A and G2447U 
mutations have been reported in linezolid-resistant clinical 
isolates of staphylococci and these mutations have also been 
shown to confer linezolid resistance in in vitro selected 
mutants of E. coli and Mycobacterium smegmatis [38, 46].
4.2  Resistance Caused by Alterations  
in 23S rRNA Modification
Ribosomal RNA is intrinsically modified with methyl groups 
and pseudouridine residues, and these modifications are 
clustered at functional centers on the ribosome. Methylations 
can also be an acquired trait, and it is well established that 
RNA modifications placed at or near an antibiotic-binding 
site can affect drug binding to the ribosome [73]. Resistance 
generally occurs either by the inactivation of an indigenous 
methyltransferase or the acquisition of an antibiotic resis-
tance methyltransferase.
Some housekeeping modifications at the PTC are shown 
to affect linezolid susceptibility. The pseudouridylation of 
23S rRNA nucleotide 2504 confers reduced susceptibility to 
linezolid, clindamycin, and tiamulin, suggesting that this 
modification may have evolved as an intrinsic resistance 
mechanism to protect bacteria from PTC-binding antibiotics 
[74]. Inactivation of the methyltransferase targeting G2445 in 
23S rRNA results in decreased susceptibility to linezolid in 
Streptococcus pneumoniae [43, 75]. Likewise, a mutation 
inactivating the methyltransferase RlmN that methylates 23S 
rRNA at the C2 position of A2503 also results in slightly 
lowered linezolid susceptibility in S. aureus [76, 77]. None 
of these mechanisms of linezolid resistance or reduced sus-
ceptibility has yet been shown to be of clinical importance, 
either because of nonoccurrence or not being revealed yet. 
This is in contrast to the only known transferable form of 
linezolid resistance conferred by the multi-resistance gene 
cfr that has been found in many clinical strains, especially in 
Staphylococcus. Cfr encodes an rRNA methyltransferase 
[78] that adds a methyl group at the C8 position of the 23S 
rRNA nucleotide A2503 [79], a position interacting directly 
with linezolid and where mutations have shown to result in 
resistance (see Fig. 22.3). The methylation confers some 
resistance to linezolid as well as resistance to five other 
classes of antibiotics that bind at overlapping nonidentical 
sites at the PTC [80, 81]. A direct interference of the 
 methylation with drug binding is supported by the X-ray 
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Fig. 22.3 A secondary structure 
model of the peptidyl transferase 
loop of domain V of 23S rRNA 
(E. coli sequence and 
numbering). Blue triangles: 
nucleotides that form the 
linezolid-binding pocket, gray 
circles: mutations that confer 
linezolid resistance with bold 
type for nucleotides where 
mutations have a considerable 
effect on linezolid MIC and 
regular type for mutations with a 
small to moderate effect. 
Organisms: E. coli (Ec), S. aureus 
(Sa), S. epidermis (Se), S. 
haemolyticus (Sh), S. pneumoniae 
(Sp), E. faecalis (Es), E. faecium 
(Em), Mycobacterium smegmatis 
(Ms), M. tuberculosis (Mt), and 
Halobacterium halobium (Hh) 
[32, 38, 40–54]. Asterisks 
indicate mutations found in 
clinical isolates
E. Ntokou and B. Vester
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structures of linezolid bound to the Deinococcus radio-
durans and H. marismortui 50S subunits [35, 36].
The cfr gene was originally discovered on multi- 
resistance plasmids isolated during surveillance studies of 
florfenicol resistance in Staphylococcus spp. of animal ori-
gin [82, 83]. In 2005, the first cfr-positive clinical strain of 
a methicillin- resistant S. aureus was reported from a 
patient briefly treated with linezolid [84]. The strain had 
cfr on the chromosome together with the ermB gene on a 
transposable genetic element and the co-expression of 
these two rRNA methyltransferase genes conferred resis-
tance to all clinically relevant antibiotics that target the 
large ribosomal subunit [81]. Since then a large number of 
staphylococcal clinical isolates  containing cfr in different 
genetic contexts have been found around the world [85–
90]. In some instances, a connection between the resistant 
isolates and prior linezolid treatment can be documented 
(i.e., see section on clinical linezolid- resistant strains 
below). The cfr gene has also been identified in other 
pathogenic bacteria, both Gram-positive and Gram- 
negative, often from animals and with no relation to line-
zolid treatment. The presence of cfr on mobile genetic 
elements such as plasmids and transposons in different 
geographical locations strongly suggests that it can be dis-
seminated within the microbial community and spread 
among pathogenic bacteria, thus conferring resistance to 
linezolid without prior exposure to the drug.
4.3  Linezolid Resistance and a Conceivable 
Relationship to Mutations in Ribosomal 
Proteins L3
Mutations in the ribosomal L3 protein have recently 
received attention as a linezolid resistance determinant. 
The main part of ribosomal protein L3 is positioned on the 
surface of the large ribosomal subunit, but a loop extends 
into the PTC near the linezolid-binding site. Bacterial L3 
mutations have been associated with resistance to line-
zolid, tiamulin/valnemulin, and anisomycin, that all bind 
to overlapping sites at the PTC [3]. The first L3 resistance 
mutation in bacteria was detected by selection with tiamu-
lin, and its role in resistance was verified by transfection 
and plasmid-coded mutant L3 expression [91]. Since then, 
a number of studies have asso ciated L3 mutations with 
linezolid resistance in various staphylococci and few other 
clinical relevant pathogens. A selection of some of these is 
displayed in Table 22.1. As evident in the table, most of 
the L3 mutations are present together with one or two 
other resistance determinants, namely 23S rRNA muta-
tions and the cfr gene. Unfortunately, most of the studies 
presenting L3 mutations do not provide evidence that the 
L3 mutations are the direct cause of  resistance. Seemingly, 
only Cfr and the 23S rRNA mutations give a medium to 
high resistance and it might be that the appearance of the 
L3 mutations are merely a selection to adopt to changes in 
the 23S rRNA (see section discussing fitness cost below). 
Nevertheless, the positions of most of the L3 mutations are 
relatively close to the linezolid binding in the ribosome 
with the closest being at a distance of approximately 7 Å 
[3]. Also, the relation between decreased susceptibility to 
the pleuromutilins retapamulin and tiamulin and L3 muta-
tions in the same region [46, 98, 105, 106] supports the 
relation between L3 mutations and linezolid resistance, as 
pleuromutilins and linezolid bind at overlapping sites in 
the PTC but are otherwise very different [80]. There are 
also reports about L3 mutations that have been detected in 
linezolid susceptible strains and are therefore not consid-
ered relevant to linezolid resistance (e.g., L101V that is 
positioned far from the PTC [100]). At the moment, it is 
difficult to establish exactly which L3 mutations do have a 
relation to reduced linezolid susceptibility, although the 
circumstantial evidence point to the part of the L3 protein 
nearest to PTC with some variations between species. One 
study of in vitro development of linezolid resistance in M. 
tuberculosis, as well as findings in clinical isolates, does 
provide strong evidence for the involvement of an L3 
C154R mutation in linezolid resistance [103]. This is also 
supported by another finding concerning the same L3 
mutation plus a neighboring mutation in clinical samples 
of M. tuberculosis [104].
4.4  Other Aspects of Linezolid Resistance: 
Fitness Cost, Cross-resistance, 
and Enhancement of Growth
In addition to reports about L3 mutations there are also 
reports about L4 mutations related to linezolid resistance [3]. 
Part of the ribosomal protein L4 is also placed relatively 
close to the PTC, but in the tunnel through which nascent 
peptides exit the ribosome [3]. Again, most studies do not 
prove a relationship between L4 mutations and resistance 
effects, except for a surveillance study of S. pneumoniae 
with a six-nucleotide deletion in the L4 gene (ΔW65-R66) 
in one strain and a neighboring six-nucleotide deletion 
(ΔK68-G69) in another strain [107]. These deletions caused 
a slightly reduced susceptibility to linezolid, as evident by 
transformations, and were associated with a fitness cost [107]. 
The amino acid deletions are located in the same region as 
mutations known to be involved in macrolide resistance 
[108], and as macrolide antibiotics bind to a site neighbor-
ing, but not directly overlapping, the linezolid-binding site, 
we imagine the effect of these deletions is probably caused 
by an allosteric mechanism. In general, the L4 mutations 
presented in relation to linezolid resistance do not present a 
22 Resistance to Linezolid
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consistent pattern and it is not definitively established which 
changes, if any, contribute directly to linezolid resistance.
Another potentially important resistance determinant is 
the presence of efflux pumps. Linezolid is not well suited for 
fighting Gram-negative pathogenic bacteria because they are 
intrinsically resistant due to efflux pumps that force linezolid 
out of the cell faster than it can accumulate [109, 110]. For 
example, a remarkably high linezolid MIC at 256 μg/mL (a 
102-fold increase) was seen after cloning of a putative 
 multidrug efflux pump from a Vibrio cholerae to a plasmid in 
a hypersensitive E. coli [111]. It is thus not surprising that 
changes in efflux in Gram-positive bacteria may influence 
the effect of linezolid. It has been shown that S. aureus pos-
sesses a gene for a major facilitator superfamily type multi-
drug efflux pump named LmrS that is capable of extruding 
linezolid [112]. Linezolid resistance caused by mutations 
Table 22.1 A selection of mutations in L3 that have been associated with linezolid resistance in staphylococci and Mycobacterium tuberculosis
L3 mutations Organism Remarksa Reference
ΔF127-H146 S. aureus In vitro selected mutant [92]
Q136H/H146Δ S. aureus L4-G69A/T70P/G71S [93]
G137A/L94Vb S. epidermidis 2576 T [55]
G139R S. aureus T, 2576 T [94]
G139R/M156T S. hominis T, 2576 T [95]
ΔS145 S. aureus [96]
ΔS145/H146Y S. aureus cfr [97]
H146R/M156T/L101Vb S. epidermidis T, 2215A, 2576 T, L4-ins70G [98]
H146Q/V154L/A157R/L101Vb S. epidermidis T, L4- ins70G/c [98]
H146Q/L94Vb S. epidermidis L4-71GGR72/c [55]
H146Q/V154L S. epidermidis 2319U, L4-71GGR72 [93]
H146Q/V154L/A157R S. epidermidis C2534T, L4-71GGR72 [99]
F147L S. epidermidis cfr [93]
F147L/L94Vb S. epidermidis L4c [55]
F147L/L94Vb S. epidermidis cfr, L4-G71D/c [55]
F147I/L101Vb S. epidermidis T, 2576 T [98]
F147I S. hominis T, 2576 T [95]
F147L/A157R/L101Vb S. epidermidis cfr, L4c [100]
F147L/A157R/L101Vb S. epidermidis L4-K68R/c [100]
G152D S. aureus In vitro selected mutant, 2447 T [92]
G152D S. aureus T [94]
G152D S. haemolyticus cfr [87]
G152D/D159Y/L101Vb S. epidermidis T, 2504A/2534 T [51]
G152D S. epidermidis 90 % T, +/− cfr, +/− 2576 T [90]
G152D/D159E/A160P/L94Vb S. epidermidis T, 2504A, 2530A, 2631U [101]
G155R S. aureus In vitro selected mutant [92]
G155R/M169L S. aureus In vitro selected mutant [92]
M156T S. haemolyticus T, cfr, 2576 T [88]
A157R S. epidermidis 2447 T [96]
S158Y/D159Y/L101Vb S. epidermidis cfr [102]
S158F/D159Y S. cohnii cfr, L4-N20S/A133T/V155I [102]
Y158F S. cohnii cfr [87]
ΔM169-G174 S. aureus cfr [97]
C154R M. tuberculosis In vitro selected mutant [103]
C154R M. tuberculosis +/− 2061 T [104]
H155R M. tuberculosis [104]
All isolates are clinical except from the ones depicted as “In vitro selected mutant”. Information about treatment with linezolid was omitted for the 
strains from reference [55], because of inadequate data. The L3 positions are according to the various organisms and can thus correspond to similar 
positions although they have different numbering
aSelected additional information: treatment with linezolid (T), contain cfr gene (cfr), potential additional resistance determinants (xxxxN refers to 
23S rRNA positions corresponding to E. coli 23S rRNA, L4-…. indicate additional mutations)
bL3 mutations that are considered strain markers and not relevant for antibiotic resistance are only included when found together with other 
mutations
cL4-N158S, which is not expected to influence linezolid resistance
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increasing the expression of ATP-binding cassette (ABC) 
transporter genes has been observed in S. pneumoniae  
[43, 75]. The mutations were found by genome sequencing 
of a linezolid-resistant strain and the effect was analyzed by 
gene disruption experiments [43]. A follow-up study involv-
ing stepwise increase of resistance by genome transforma-
tion supported the role of a specific mutation that increased 
expression of an ABC transporter as a resistance determinant 
[75]. However, not surprisingly, such changes may come 
with a cost in growth rate. Future experiments might reveal 
if efflux is a significant factor in linezolid resistance or not. 
As a general lesson from research on antibiotic resistance, 
starting to look might greatly enhance the insight.
It is one thing for bacteria to obtain a resistance deter-
minant but another thing to sustain it and to avoid being 
 outgrown by nonresistant neighbors. The maintenance and 
spread of resistance genes is related to their fitness cost. 
Expression of the linezolid resistance determinant Cfr in a 
laboratory strain had only a small effect on growth rate [113]. 
Such low fitness cost is troublesome as it suggests that cells 
can maintain a gene even in the absence of antibiotic selec-
tion. Competition experiments showed that cells with an 
inactivated rlmN gene (i.e., showing slightly lowered line-
zolid susceptibility, as mentioned above) outcompeted 
S. aureus wild-type cells under linezolid selection [77]. The 
fitness cost of resistance mutations varies, and is also depen-
dent on the specific organism. A decrease in growth rates for 
23S rRNA mutations at the PTC is expected because many 
of the nucleotides are phylogenetically conserved and are 
considered functionally important. For example, the single 
mutations in the PTC area of 23S rRNA in M. smegmatis that 
have the most significant effects on linezolid resistance show 
either a moderate (A2503G/U and G2447U) or a large 
(U2504G and G2576U) decrease in growth rate, where the 
G2576U mutation with the largest resistance effect results in 
a threefold slower growth [48, 50, 66]. This is consistent 
with the fact that although both the G2447U and G2576U 
mutations lead to 32-fold increases in linezolid MIC values, 
only the G2447U mutation was isolated by selection in the 
presence of linezolid [38, 48]. The G2576U mutation has 
also been studied extensively in S. aureus, where a progres-
sive decrease in growth rate is observed with each additional 
23S rRNA gene copy harboring the mutation [60]. However, 
the ability of the mutation to persist in one copy in the 
absence of antibiotic selection and the rapid reemergence of 
multiple mutated copies upon reexposure to linezolid sug-
gests that a single copy has a minimal fitness cost [114]. 
Such a resistance mutation may be accompanied by other 
mutations that compensate for deleterious effects or act 
 synergistically to enhance resistance. An example is the step-
wise genome transformation study mentioned above [75], 
where linezolid resistance by G2576U in 23S rRNA comes 
with a fitness cost that can be counteracted by an L3 muta-
tion at position Y137H in S. pneumoniae. The study shows 
that the L3 mutation alone does not confer reduced suscepti-
bility to linezolid. The mutation corresponds to the L3 F147L 
mutation in S. epidermis that has been related to linezolid 
resistance in several studies (Table 22.1). It remains to be 
established how many of the mutations in Table 22.1 are true 
resistance determinants and how many are compensatory 
“fitness cost” mutations or just random mutations without 
any phenotypic effect. A possibly related matter has recently 
been published concerning linezolid-resistant S. epidermis 
strains that grow better in the presence of linezolid than in 
the absence, and which contained mutations at positions 
U2504A and C2534U in 23S rRNA together with L3 muta-
tions G152D and D159Y [51]. Also, a synergistic effect of 
linezolid resistance determinants has been verified in S. epi-
dermis with cfr plus C2534U in 23S rRNA (in two of six 
alleles) plus mutations in L3 and L4 [99]. Possible synergis-
tic effects have also been reported for other PTC antibiotics 
in other bacteria such as M. smegmatis [48] and Brachyspira 
spp. [115, 116], indicating interplay between multiple muta-
tions in relation to resistance, accommodation of mutations, 
and fitness cost. More specific information about the effects 
of the single and combined mutations is needed to elucidate 
their detailed interactions.
It was anticipated that purely synthetic compounds like 
linezolid would not show cross-resistance, but maybe 
cross- resistance is more a matter of sharing binding sites 
than being chemically similar. The efflux pumps that expel 
linezolid also work on other compounds [110, 112]. The 
methylation performed by Cfr provides linezolid resis-
tance as well as resistance to five other classes of antibiot-
ics [80, 81]. Examples of cross-resistance between PTC 
antibiotics resulting from 23S rRNA mutations have been 
observed [48, 66, 116, 117], although no straightforward 
relationship between overlapping binding sites and cross-
resistance was found. There is a correlation between line-
zolid and chloramphenicol resistance for the single 
G2447U, A2503G, U2504G, G2505A, and G2576U muta-
tions in M. smegmatis [48, 66]. However, this correlation 
does not apply for G2032A-U2504G and C2055A-U2504G 
double mutations and no relationship between linezolid, 
clindamycin, and valnemulin resistance could be observed 
[48, 66]. In addition, cross-resistance between linezolid 
and tiamulin has been documented for the G2447U and 
U2500A mutations in E. coli and the G2576U mutation in 
E. coli and S. aureus [46]. The different sets of specific 
bacteria, mutations and antibiotics reported in the litera-
ture preclude simple and common conclusion, and more 
information is needed.
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5  Linezolid Resistance Among Clinical 
Isolates
As already mentioned, linezolid has a broad spectrum of 
activity against various Gram-positive clinical strains includ-
ing S. aureus, CoNS, E. faecalis, E. faecium, S. pneumoniae, 
viridans group and other streptococci, β-hemolytic strep-
tococci and other rarely isolated Gram-positive human 
 pathogens [118]. It is also widely used to treat infections 
from multidrug-resistant (MDR) clinical isolates such as 
methicillin- resistant S. aureus (MRSA) and vancomycin- 
resistant enterococci (VRE) [119–125].
Clinical isolates with resistance to linezolid were first 
documented in 1999 and included two isolates from 2/169 
patients (1.2 %) receiving linezolid treatment for enterococ-
cal infections [14]. Both of the patients received linezolid for 
a long period of time in order to treat bacteraemia associated 
with intravascular devices. The first report of a clinical iso-
late of methicillin-resistant S. aureus with linezolid resis-
tance was reported in 2001 and was isolated from an 
85-year-old man who had received prior linezolid treatment 
[15]. The resistance was due to G2576U mutations in the V 
domain of the 23S rRNA [15]. The first report of cfr as a 
resistance determinant in a clinical staphylococcal isolate 
was in 2008 from the USA through the surveillance program 
LEADER [86].
Documented resistance to linezolid appears to be spo-
radic and can occur in outbreaks [118, 126–131]. In most 
cases of sporadic clinical isolates exhibiting resistance to 
linezolid, the resistance was associated with prior linezolid 
therapy [39, 63, 132–134] although there have been reports 
of rapid emergence of resistance after short-term treatment 
[135], or resistance not related to prior treatment with line-
zolid [136, 137].
Due to the widespread use of linezolid for treating noso-
comial infections by MDR staphylococcal and enterococcal 
clinical isolates, a need immerged to monitor the spectrum 
and potency of linezolid and for that two surveillance pro-
grams have been established. The original surveillance pro-
gram for linezolid was ZAPS (Zyvox Activity and Potency 
Surveillance) [129, 138–140] and was renamed ZAAPS, 
enrolling medical centers in Latin America (LATAM), Asia 
Pacific (APAC), and Europe [127, 130, 131, 141, 142]. The 
second surveillance program is the LEADER surveillance 
program and it has monitored linezolid activity, spectrum, 
and resistance rates in the USA since 2004 [121, 143–147]. 
The most recent results from the LEADER surveillance pro-
gram are from 2011, and monitored 7303 Gram-positive 
clinical isolates from 60 medical centers. It shows that 
 resistance to linezolid is particularly rare in clinical MRSA 
(≤0.2 %) and CoNS (≤1.2 %) [148]. Linezolid was one of 
the most active agents among 1160 enterococcal strains 
(66 % E. faecalis, 30.6 % E. faecium) with a susceptibility 
rate of 99.7 %. The most important finding in this surveil-
lance program was a nonsusceptible viridans group strepto-
coccus, Streptococcus sanguinis (MIC >8 μg/mL), that was 
encountered for the first time in this program [148]. In the 
same manner, the latest ZAAPS Program report tested line-
zolid and comparators against 7972 Gram-positive clinical 
isolates from 73 medical centers (33 countries) from five 
continents, in order to summarize its activity and spectrum. 
Resistance to linezolid occurred in ≤0.1 % of strains of 
S. aureus, ≤0.9 % of CoNS, and ≤0.3 % of enterococcal 
strains [93]. Although the results from the two surveillance 
programs appear to be encouraging, concerns are lately 
raised by the appearance of linezolid-resistant clinical iso-
lates in multiple studies around the world. Enterococcal 
 clinical isolates resistant to linezolid due to L3 mutations and 
S. cohnii clinical isolates resistant to linezolid harboring the 
cfr and the 23S rRNA mutation G2576U were documented 
from a multicenter study in China [149]. A study conducted 
on clinical isolates of CoNS from two hospitals in China 
reports the emergence of cfr-harboring CoNS [150]. Emer-
gence of linezolid- resistant S. aureus from cystic fibrosis 
(CF) patients was documented in Ohio with isolates having 
L3 mutations or the 23S rRNA mutation G2576U, raising 
serious concerns for CF patients [94]. Linezolid-resistant 
clinical isolates of E. faecium were isolated in Ontario, 
Canada, from 2010 to 2012 in a study that documents the 
first appearance of cfr in a clinical isolate of E. faecium 
[151]. A linezolid-resistant S. pneumoniae isolate with a 
linezolid MIC at 4 μg/mL was encountered for the first time 
in the LEADER Program results for 2010, and molecular 
characterization indicated that this strain had wild-type 23S 
rRNA and L22 ribosomal protein DNA sequences but had 
mutations in the ribosomal protein L4: Q67K and G69V [152].
Concerns also rise by studies that document the dissemina-
tion of the cfr gene among linezolid-resistant clinical isolates 
of various species [87, 150, 151, 153–155]. In a recent study 
from China, linezolid-resistant staphylococcal clinical isolates 
had the cfr gene located on a plasmid segment identical to a 
sequenced 14 kb cfr-carrying segment, from the plasmid pSS-
02 [87]. This plasmid was originally identified in staphylococci 
isolated from pigs. This finding indicates that closely related—
if not identical—plasmids carrying the cfr gene can be 
exchanged between CoNS from animals and methicillin-resis-
tant CoNS (MRCoNS) from humans and that these MRCoNS 
can be involved in severe infections in humans [87].
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6  Clinical Significance of Linezolid 
Resistance and Concluding Remarks
Linezolid remains highly active against most staphylococci, 
and its value in treating serious infections caused by MRSA has 
been well documented. Its availability as an oral formulation 
makes it desirable for outpatient treatment [128]. However, up 
to a quarter of patients prescribed the oral formulation of line-
zolid are non-adherent with therapy [156].
Among patients treated with linezolid for extended peri-
ods, resistance rates may be significantly elevated as com-
pared with data reported in surveillance studies. Clinicians 
should remain aware that linezolid resistance may arise fol-
lowing prolonged treatment with linezolid and of the possi-
bility of linezolid-resistant staphylococci (LRS) in patients 
that have not been previously treated with linezolid, given 
the high incidence of LRSA carrying cfr [128]. As an exam-
ple, cystic fibrosis patients with respiratory tract infections 
caused by S. aureus have LRSA rates of up to 11 %, related 
to the number and length of linezolid treatments [94]. In 
addition, linezolid resistance may be underreported based on 
technical complications in the interpretation of both MIC 
and disc diffusion results [157]. Compared with the Clinical 
and Laboratory Standards Institute broth microdilution refer-
ence method, one study demonstrated 8/15 (53.3 %) LRS 
were falsely reported susceptible by disc diffusion and 6/15 
(40.0 %) by Etest [157].
Treatment options for linezolid-resistant isolates are lim-
ited, so susceptibility testing for linezolid resistance should 
be considered prior to using linezolid for serious infections. 
In addition, judicious use of linezolid, accurate identification 
of resistance, and application of strict infection control mea-
sures are essential to the preservation of linezolid as a thera-
peutic agent. Also, it is very important to clearly identify all 
linezolid resistance determinants. It is obvious that linezolid 
resistance may occur both as transmissible element (cfr 
gene) and as acquired ribosomal mutations and probably as 
efflux changes caused by mutations. It is possible that devel-
opment of derivatives of linezolid can overcome some of the 
resistance determinant and there seems to be steps in this 
direction.
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